Today on DrugResearcher.com   Biogen antibody regenerates MS nerves FDA told its safety monitoring of clinical trials not good enough BMS shows off cancer drug as it waits for regulator decision ABI and Olink to push protein detection sensitivity 'In-house' outsourcing firm in line for EU accolade

Related Industry News   Drug theft costs industry up to $1bn a year Mitsubishi/Tanabe merger makes Japan's fifth biggest drugmaker One in the eye for systemic therapy Indian clinical research: benefits and challenges

Breaking News on Drug Discovery
Daily  Tuesday 02 October 2007		Forward to a colleague

	Product Brochure Unique Process technology for drying very small quantities of API ProCepT's R&D Drying Technology for small quantities of API; SPRAY DRYING - NUTSCHE FILTER DRYING - AGITATED VACUUM DRYING - MICROWAVE DRYING. Fully instrumented and automated for Maximum of process knowledge with Minimum of API in a Minimum of time! Make use of the ProCepT lab... Click Here Access Full Stories Biogen antibody regenerates MS nerves Biogen Idec is pushing forward with a therapeutic antibody that can turn myelin producing cells back on and so could reverse the damaging effects of multiple sclerosis (MS)... Read FDA told its safety monitoring of clinical trials not good enough The US Food and Drug Administration (FDA) has been called into question again after the release of a damning report, this time suggesting the agency is inadequate in its safety monitoring of clinical trials... Read BMS shows off cancer drug as it waits for regulator decision With a regulator decision looming ever closer, Bristol-Myers Squibb (BMS) has set out to woo European oncologists with its first-in-class breast cancer drug... Read ABI and Olink to push protein detection sensitivity Applied Biosystems (ABI) has exclusively licensed Olink Bioscience's proximity ligation assay (PLA) technology that enables the correlation of gene and protein expression data... Read 'In-house' outsourcing firm in line for EU accolade Synergy has been short-listed in three categories for the upcoming European Outsourcing Awards - an accolade that could give a boost to its innovative "in house" outsourcing model... Read
	All News Headlines for: October | September | August
	Application Notes Separation of polar compounds A Mini-tutorial to HILIC The ZIC®-HILIC column is the ideal choice for separation of polar and hydrophilic compounds. Amino acids, bases, peptides, carbohydrates, plant extracts and other polar compounds have good retention on the column from SeQuant - "The Number One in HILIC"... Click Here
	Related Industry News Drug theft costs industry up to $1bn a year Pharmaceutical companies not only have to face the consequences of a burgeoning counterfeit drug black market but have to contend with the theft of their own manufactured drugs for illicit uses, according to a... Read Mitsubishi/Tanabe merger makes Japan's fifth biggest drugmaker The marriage of Mitsubishi Tanabe creates a new entity looking to expand its presence outside Japan and create a more efficient R&D and manufacturing machine... Read One in the eye for systemic therapy TheraKine and Capsulution NanoScience are collaborating to develop new drug delivery systems to aid in the treatment of serious eye diseases... Read Indian clinical research: benefits and challenges Outsourcing-Pharma.com explores the three main benefits and challenges of conducting clinical research in India... Read Inside India: special series Clinical trials in India: 'The wind is blowing' An industry veteran gives Outsourcing-Pharma.com an update on the state of the contract research organisation (CRO) industry in India. Read Product Brochure A revolution in Sales Lead Generation! - Free Download Promote your products and technology towards our readers, and we'll build a detailed profile of each person who reads your presentation document... Download our FREE Smart Lead Generation brochure now!... Click Here Previous Headlines Personalised medicine boosted by new cancer target A new target for anticancer drugs is over expressed in cancer cells to a much greater extent than other oncogenes, boosting the prospects of personalised therapy in the field... Read Pfizer's Nigerian court trial over Trovan scandal to kick off Pfizer will appear this week in a Nigerian court to face allegations that it caused the death of Nigerian children over a decade ago when it conducted a clinical trial of its meningitis drug Trovan (trovafloxacin)... Read Novartis weighs up label-free HTS for drug discovery Researchers from Novartis have published results using high-throughput screening (HTS) mass spectrometry (MS) techniques for the identification of enzyme inhibitors... Read Synta reawakens 40-year-old anticancer mechanism Although it is over forty years since scientists realised cancer cells don't have the anti-oxidant protective capabilities of normal cells, it seems that only one pharma company has developed a drug to exploit... Read Novartis diabetes drug gets thumbs up in EU Novartis's potential Type II diabetes blockbuster has been given the green light in the EU after receiving approval... Read Product Information - brochures, Web centers Separation of polar compounds - Application Notes Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analysis and instrumentation Assays and screening Cell culture & Equipment Chromatography Compounds and consumables Contract services (outsourcing) Drug discovery Genomics / Proteomics Informatics & IT Lab equipment & consumables Liquid handling and automation Liquid handling and sample preparation Production technologies Separation and purification

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com